Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Interferons alpha (IFNs-alpha) are pleiotropic cytokines belonging to the type I IFN family, originally described for their antiviral activity. These cytokines exhibit a long record of clinical use in patients with some types of cancer and viral diseases. Notably, certain autoimmune disorders have been postulated to be mediated by endogenous IFN-alpha and are often observed in some IFN-treated patients. IFN-alpha can induce multiple biological effects, including induction/promotion of apoptosis and inhibition of cell growth. In addition, these cytokines promote the differentiation and activity of host immune cells. Early studies in mouse tumor models showed the importance of host immune mechanisms in the generation of a long-lasting antitumor response after injection of the animals with either IFN or tumor cells genetically modified for IFN-alpha production. Several studies have shown that IFN-alpha can induce the rapid differentiation of monocytes into highly activated dendritic cells (DCs). Of note, these DCs (IFN-DCs) are particularly effective in taking up complex antigens and inducing T- and B-cell immunity. The ensemble of these results suggests that IFN-DCs can play a role in the generation of antitumor T-cell immunity, pointing out that these cells could be successfully used in strategies of cancer immunotherapy. Likewise, IFN-alpha-DC interactions could also play a role in the pathogenesis of some autoimmune disorders, often associated with IFN-alpha treatment. All this reveals the complexity of the IFN-alpha-DC interactions under normal and pathological conditions and stimulates further studies for identifying optimal modalities in either using these cytokines or controlling their production/action in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“[47] van Elsas A, Hurwitz AA, Allison JP.”
Background
Cited by
Immunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
Type I interferon: friend or foe?
Trinchieri, G. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20101664 · Cited by 844
Triggers and drivers of autoimmunity: lessons from coeliac disease
Sollid, L. M., & Jabri, B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3407 · Cited by 331
Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles
Li, J., Ai, Y., Wang, L., Bu, P., Sharkey, C. C., Wu, Q., Wun, B., Roy, S., Shen, X., & King, M. R. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.046 · Cited by 313
Berger Rentsch, M., & Zimmer, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025858 · Cited by 269
“An issue of increasing importance is the determination of neutralizing antibodies that are induced in some patients following recombinant IFN therapy [10] .”
Background
Metadata
- Authors
- Rizza, P., Moretti, F., & Belardelli, F.
- Venue
- Autoimmunity
- Publisher
- Informa UK Limited
- Published
- 2010-02-26
- Volume
- 43
- Issue
- 3
- Pages
- 204-209
- ISSN
- 0891-6934 (ISSN-L)
- 1607-842X
- OpenAlex
- W2037468153
- Cited by
- 109
- References
- 1
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity. https://app.cochat.ai/papers/10.3109/08916930903510880
- The paper
- Rizza, P., Moretti, F., & Belardelli, F. (2010). Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity. Autoimmunity. https://doi.org/10.3109/08916930903510880
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.